Cibus, Inc. CBUS
1.14 USD -0.10 (-8.06%)
At closeNov 3, 2026, 4:00 PM EST
1.14 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
1.12 Day range 1.29
1.09 52-week range 4.19
- YTD
- -34.48%
- 1 year
- -21.38%
- Market cap
- 87.13M
- Revenue (ttm)
- 4.15M
- EPS (ttm)
- -1.62
- Shares out
- 26.46M
- Forward P/E
- -1.09
- YTD return
- -34.48%
- 1-year return
- -21.38%
- Volume
- 123.21K
- Avg volume
- 114.14K
- Open
- 1.24
- Previous close
- 1.24
- Day's range
- 1.12 – 1.29
- 52-week range
- 1.09 – 4.19
- Beta
- 1.79
- Analysts
- Buy
- Price target
- 18.13 (+1489.9%)
15m -0.14 (-10.22%)
Key statistics
- Enterprise value
- 90.65M
- PEG ratio
- 0.00
- Price / sales
- 20.22
- Price / book
- 0.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 250.90%
- Free cash flow
- -48.61M
- Total cash
- 28.80M
- Total debt
- 36.74M
- Return on equity
- -149.74%
- Short % of float
- 12.40%
- 50-day average
- 4.14
- 200-day average
- 9.75
Analyst view
Consensus: buy
Buy
Price target (mean) 18.13 +1489.9% upside
Now 1.14
- Target (low)
- 4.00
- Target (mean)
- 18.13
- Target (high)
- 25.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy1
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.85.
Financials — quick view
CBUS Revenue — quarterly 994.00K
CBUS Net income — quarterly -22.14M
CBUS EPS — quarterly -0.29
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.90 | 0.06 | +0.96 | +106.67% |
| Aug 8, 2024 | Jun 1, 2024 | -0.81 | -1.14 | -0.33 | -40.74% |
| May 9, 2024 | Mar 1, 2024 | -1.01 | -1.12 | -0.11 | -10.89% |
| Mar 21, 2024 | Dec 1, 2023 | -1.12 | -1.16 | -0.04 | -3.57% |
| Nov 9, 2023 | Sep 1, 2023 | -1.18 | -1.59 | -0.41 | -34.75% |
| Aug 9, 2023 | Jun 1, 2023 | -0.30 | -3.05 | -2.75 | -916.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 22, 2024 | Canaccord Genuity | main | Buy | Buy |
| Sep 24, 2024 | Alliance Global Partners | main | Buy | Buy |
| Sep 19, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 12, 2024 | Canaccord Genuity | main | Buy | Buy |
| Jul 29, 2024 | Alliance Global Partners | init | — | Buy |
About Cibus, Inc.
Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cibus.com
News
Cibus to Report Third Quarter 2026 Financial Results on November 12, 2026 After the Market Close and Host Conference Call 
Crystal Crop Protection And Cibus Announce Agreement To Develop Gene-Edited Traits In Brassica Juncea 
Cibus and Crystal Crop Protection Team Up to Improve India's Mustard Crop 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Cibus, Inc. (CBUS) Q2 2026 Earnings Call Transcript 
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates 
Cibus Q2 Earnings Call Highlights - Transcript: Cibus Q2 2026 Earnings Conference Call
12 Health Care Stocks Moving In Thursday's After-Market Session 
Cibus Q2 EPS $(0.29) Misses $(0.26) Estimate, Sales $994.000K Miss $1.704M Estimate
Your note
Sign in to keep a note on CBUS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROOS CORNELIS | Chief Financial Officer | Sale | Nov 11, 2024 | 74,197 |
| CARR MICHAEL A | Chief Executive Officer | Stock Award(Grant) | May 30, 2023 | 33,174 |
| FREY TRAVIS | Chief Technology Officer | Stock Award(Grant) | May 30, 2023 | 19,060 |
| FRIMERMAN DEBRA H. | General Counsel | Stock Award(Grant) | May 30, 2023 | 18,772 |
| GOCAL GREG FRANCIS WILLIAM | Officer | Sale | Jul 14, 2024 | 314,844 |
| KING WADE HAMPTON M.D. | Chief Financial Officer | Stock Award(Grant) | May 30, 2023 | 212,100 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.79% | 3,913,279 | 11.11M | Sep 29, 2024 |
| Vantage Consulting Group, Inc | 4.32% | 1,143,949 | 3.25M | Sep 29, 2024 |
| Blackrock Inc. | 4.04% | 1,068,342 | 3.03M | Sep 29, 2024 |
| Vanguard Group Inc | 3.17% | 838,952 | 2.38M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.38% | 364,923 | 1.04M | Sep 29, 2024 |
| State Street Corporation | 1.16% | 307,262 | 872.62K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 4.61% | 1,218,674 | 3.46M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.76% | 465,386 | 1.32M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.45% | 382,284 | 1.09M | Oct 30, 2024 |
| Fidelity Growth Company K6 Fund | 1.41% | 373,153 | 1.06M | Oct 30, 2024 |
| Fidelity Series Growth Company Fund | 1.26% | 332,232 | 943.54K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.00% | 264,388 | 750.86K | Sep 29, 2024 |